Centre for Medicine and Oral Health, Griffith University - Gold Coast GH1, High Street, Southport, Gold Coast, QLD 4215, Australia.
Cancer Lett. 2010 Jul 1;293(1):1-14. doi: 10.1016/j.canlet.2009.11.019. Epub 2010 Feb 1.
Castrate resistant prostate cancer (CRPC) is essentially incurable. Recently though, chemotherapy demonstrated a survival benefit ( approximately 2months) in the treatment of CRPC. While this was a landmark finding, suboptimal efficacy and systemic toxicities at the therapeutic doses warranted further development. Smart combination therapies, acting through multiple mechanisms to target the heterogeneous cell populations of PC and with potential for reduction in individual dosing, need to be developed. In that, targeted molecular chemotherapy has generated significant interest with the potential for localized treatment to generate systemic efficacy. This can be further enhanced through the use of oncolytic conditionally replicative adenoviruses (CRAds) to deliver molecular chemotherapy. The prospects of chemotherapy and molecular-chemotherapy as single and as components of combination therapies are discussed.
去势抵抗性前列腺癌（CRPC）基本上是无法治愈的。然而，最近的化疗在治疗 CRPC 方面显示出了生存获益（约 2 个月）。虽然这是一个里程碑式的发现，但在治疗剂量下，疗效不理想和全身毒性需要进一步发展。需要开发智能联合治疗，通过多种机制作用于 PC 的异质细胞群，并有可能减少个体剂量。在这方面，靶向分子化疗引起了极大的兴趣，有可能进行局部治疗以产生全身疗效。通过使用溶瘤条件复制腺病毒（CRAds）来递送分子化疗，可以进一步增强这种效果。讨论了化疗和分子化疗作为单一药物以及联合治疗的组成部分的前景。
